CytomX Therapeutics, Inc. — Investor Relations & Filings
Filings indexed
752
across all filing types
Latest filing
2025-02-26
Delisting Announcement
Country
US
United States of America
Listing
US
CTMX
CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company is developing a novel class of antibody therapeutics based on its proprietary Probody® platform. This technology creates masked, conditionally activated biologics designed to be activated specifically within the tumor microenvironment. The goal of this approach is to localize therapeutic activity to the tumor, thereby creating more potent and less toxic treatments for cancer patients. CytomX is advancing a pipeline of Probody drug candidates through its own research and strategic partnerships to address various cancer types.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2025-02-26 | English | |
| Director's Dealing 2025 | 2025-02-10 | English | |
| Director's Dealing 2025 | 2025-02-06 | English | |
| Director's Dealing 2025 | 2025-02-06 | English | |
| Director's Dealing 2025 | 2025-02-06 | English | |
| Director's Dealing 2025 | 2025-02-06 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
8 filings
| |||||
| 12391155 | 8-K | 2025-02-26 | English | ||
| 12391156 | Director's Dealing 2025 | 2025-02-10 | English | ||
| 12391157 | Director's Dealing 2025 | 2025-02-06 | English | ||
| 12391158 | Director's Dealing 2025 | 2025-02-06 | English | ||
| 12391159 | Director's Dealing 2025 | 2025-02-06 | English | ||
| 12391160 | Director's Dealing 2025 | 2025-02-06 | English | ||
| 12391161 | 8-K | 2025-02-03 | English | ||
| 12391162 | 8-K | 2025-01-06 | English | ||
|
2024
7 filings
| |||||
| 12391163 | AMENDMENT NO. 3 TO SCHEDULE 13G | 2024-11-14 | English | ||
| 12391164 | AMENDMENT NO.3 | 2024-11-14 | English | ||
| 12391165 | Major Shareholding Notification 2024 | 2024-11-14 | English | ||
| 12391166 | 8-K | 2024-11-07 | English | ||
| 12391167 | 10-Q | 2024-11-07 | English | ||
| 12391168 | Director's Dealing 2024 | 2024-08-22 | English | ||
| 12391169 | Director's Dealing 2024 | 2024-08-22 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
CytomX Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32770/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32770 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32770 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32770 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32770}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CytomX Therapeutics, Inc. (id: 32770)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.